ObjectiveTo observe the effect of methotrexate combined with Zhengqing Fengtongning sustained release tablets in the treatment of active rheumatoid arthritis. MethodsA total of 120 patients with active rheumatoid arthritis were selected as research subjects and randomly divided into a study group or a control group, with 60 patients in each group. The control group was treated with non-steroidal anti-inflammatory drugs combined with methotrexate, based on which the study group was treated with Zhengqing Fengtongning sustained release tablets additionally; both groups were treated for 12 weeks. The followings were compared between the two groups before the treatment and after the 12-week treatment, including the joint condition, pain Visual Analog Scale (VAS) score, Disease Activity Score 28 (DAS28) score, Generic Quality of Life Inventory 74 (GQOL-74) score, and the laboratory indicators （rheumatoid factor ［RF］, erythrocyte sedimentation rate ［ESR］, C-reactive protein ［CRP］）, as well as the clinical effect after the 12-week treatment. ResultsAfter the 12-week treatment, the time for morning stiffness, numbers of joints with tenderness, numbers of swelling joints, pain VAS scores, DAS28 scores, as well as the RF, ESR, and CRP levels decreased, while the gripping power and GQOL-74 scores increased in the two groups. The aforementioned indexes were superior in the study group than in the control group (all P＜0.05). After the 12-week treatment, the study group had a higher total effective rate than the control group (93.33% vs. 78.33%) (P＜0.05). ConclusionThe combined application of methotrexate and Zhengqing Fengtongning sustained release tablets can improve the clinical symptoms and life quality of patients with active rheumatoid arthritis, with a significant clinical effect, and is worth promoting.

无